Raymond James & Associates Adverum Biotechnologies, Inc. Transaction History

Raymond James & Associates

  • $161 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2018

May 14, 2018
SELL
$3.65 - $7.95 $178,850 - $389,550
-49,000 Closed
0 $0
Q4 2017

Feb 14, 2018
BUY
$2.85 - $3.95 $139,650 - $193,550
49,000
49,000 $172,000

Others Institutions Holding ADVM

# of Institutions
3
Shares Held
524K
Call Options Held
0
Put Options Held
0
View Full List

About Adverum Biotechnologies, Inc.

ADVM Quotes by TradingView
  • Ticker ADVM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 99,333,600
  • Market Cap $471M
  • Description
  • Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...
More about ADVM
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email